These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22412042)

  • 21. Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.
    Campiglio M; Sandri M; Sasso M; Bianchi F; Balsari A; Ménard S; Tagliabue E
    Ann Oncol; 2014 May; 25(5):1073-4. PubMed ID: 24558025
    [No Abstract]   [Full Text] [Related]  

  • 22. [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].
    Campone M; Frenel JS; André F; Bachelot T; Juin P
    Bull Cancer; 2012 Jun; 99(6):665-72. PubMed ID: 22614782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 aberrations in cancer: implications for therapy.
    Yan M; Parker BA; Schwab R; Kurzrock R
    Cancer Treat Rev; 2014 Jul; 40(6):770-80. PubMed ID: 24656976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous fluorescence immunophenotyping and Her-2/neu genotyping (FICTION) in breast carcinoma candidates to target therapy.
    Gatta LB; Incardona P; Cadei M; Grigolato P; Simoncelli S; Balzarini P
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):413-20. PubMed ID: 22417857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Veeraraghavan J; De Angelis C; Mao R; Wang T; Herrera S; Pavlick AC; Contreras A; Nuciforo P; Mayer IA; Forero A; Nanda R; Goetz MP; Chang JC; Wolff AC; Krop IE; Fuqua SAW; Prat A; Hilsenbeck SG; Weigelt B; Reis-Filho JS; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
    Ann Oncol; 2019 Jun; 30(6):927-933. PubMed ID: 30903140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.
    Janjigian YY; Braghiroli MI
    Surg Oncol Clin N Am; 2017 Apr; 26(2):313-324. PubMed ID: 28279471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of HER2 testing in the management of breast cancer.
    Ravdin P
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline.
    Kong H; Bai Q; Li A; Zhou X; Yang W
    Diagn Pathol; 2022 Jan; 17(1):5. PubMed ID: 34996485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical implications of intratumoral heterogeneity of HER2 gene amplification in locally advanced HER2-positive breast cancer patients.
    Hacioglu B; Akin S; Sever AR; Altundag K
    Future Oncol; 2015 Sep; 11(18):2495-7. PubMed ID: 26278702
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeted anti-HER2 cancer therapy in elderly women diagnosed with breast cancer.
    Molina-Garrido MJ; Guillen-Ponce C; Mora-Rufete A
    Anticancer Agents Med Chem; 2014 Jun; 14(5):639-45. PubMed ID: 23438846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients.
    Nakamura R; Yamamoto N; Onai Y; Watanabe Y; Kawana H; Miyazaki M
    Breast Cancer; 2013 Oct; 20(4):336-41. PubMed ID: 22367960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Her2 a paradigm for targeted therapy].
    Marijon H; André F
    Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 testing recommendations in Australia.
    Bilous M;
    Pathology; 2001 Nov; 33(4):425-7. PubMed ID: 11827407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Her-2 testing: the numbers just don't add up.
    Killeen JL
    Hum Pathol; 2004 Jul; 35(7):903-4. PubMed ID: 15257559
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.